This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
—In the Original Contribution entitled "Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome," by Fisher et al, published in the June 15, 1994, issue of The Journal (1994;271:1836-1843), an incorrect financial disclosure statement appeared. In the third footnote on page 1836, Steven M. Opal, MD, is identified as a paid consultant to Synergen Inc, Boulder, Colo, for the development of recombinant human interleukin 1 receptor antagonist. Dr Opal has not entered into a paid consultant's agreement with Synergen Inc, although he has received the standard compensation received by independent site investigators for the study and received by members of the study's Clinical Evaluation Committee.
Incorrect Financial Disclosure Statement. JAMA. 1994;272(15):1170. doi:10.1001/jama.1994.03520150036032
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: